Medizinische Universität Graz
Welcome,         Profile    Billing    Logout  
 115 Trials 
407 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Stradner, Martin
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Calendar Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis
Recruiting
2
300
Europe, Japan, US, RoW
HZN-825 BID, Placebo, HZN-825 QD
Amgen
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
10/24
09/25
Fraiser, Brittany
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Calendar Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis
Recruiting
2
300
Europe, Japan, US, RoW
HZN-825 BID, Placebo, HZN-825 QD
Amgen
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
10/24
09/25
Lackner, Angelika
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Calendar Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis
Recruiting
2
300
Europe, Japan, US, RoW
HZN-825 BID, Placebo, HZN-825 QD
Amgen
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
10/24
09/25
Rieber, Alyssa G
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Schuh, Romana
CaTO-BTK, NCT05551780: Treatment of Calcific Total Occlusions in Peripheral Artery Disease

Recruiting
N/A
130
Europe, US
SoundBite Crossing System
SoundBite Medical Solutions, Inc.
Chronic Total Occlusion of Artery of the Extremities
11/24
12/24
Anderson, Rachel Lacy
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Recruiting
3
2620
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
04/25
12/25
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
07/25
07/25
Skandera, Joanna
No trials found
 

Download Options